May 15, 2024Open Access

Supplementary Data 1 from Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study

Key points are not available for this paper at this time.

Supplementary figure and tables

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Daniel H. Ahn

Afsaneh Barzi

Maya Ridinger

Building similarity graph...

Analyzing shared references across papers